Generic medicines help maintain the country’s healthcare system, from curing patients to saving money. Currently, the price of off-label drugs is 70% to 80% lower than branded medicines. In the United States, the decline in medicine price works as the biggest catalyst for the generic drug market growth. These generic medicines prices sometimes declined to 85% less than patented drugs; this happens when various generic drug companies target a single patented drug. Our research findings suggest that the United States Off-Label Drugs market will grow with a CAGR of 5.69% in future from 2020 to 2026.
The United States government awareness for the use of generic drugs reduces overall health expenditure in the country. The FDA’s Office of Generic Drugs (OGD) within the Center for Drug Evaluation in Research ensures access to safe, high quality and affordable drugs to Americans. The U.S government made a law regarding the generic drug, allowing a new player to enter the market. Besides factors like the rising number of patients for diabetes, Alzheimer, cardiac diseases, an increasing number of drug patent expirations and government initiatives expected to drive the generic drugs industry. As per this research study, the United States Off-patent Drugs Market was US$ 171.8 Billion in the year 2020.
Generic Drug Companies Deals
On July 6, 2020, Endo announced that it had received FDA approval of Qwo® (collagenase clostridium histolyticum-aaes). Another company, named Lupin Limited manufactures generic drug Abacavir& Lamivudine, whose combination is being used together with other medications to treat human immunodeficiency virus (HIV) infection. We have covered companies’ initiatives that sell various generic drugs in the United States. Companies covered in the report are Teva Pharmaceutical Industries Ltd, Mylan N.V, Sandoz Inc, Endo Pharmaceuticals, Lupin Limited, Dr Reddy’s and Sun pharma.
Renub Research report title “United States Generic Drugs Market’’ By Segment (Generic, Branded), Therapy Area (CNS, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Anti – infective, Oncology and Others), Pharmaceutical (Branded Pharmaceutical, Generics Pharmaceutical), Company (Teva Pharmaceutical Industries Ltd, Mylan N.V, Sandoz Inc, Endo Pharmaceuticals, Lupin Limited , Dr Reddy’s and Sun pharma)” provides an all-encompassing analysis on the US Generic Drug Industry.
Request a Free Sample Copy of the Report: https://www.renub.com/request-sample-page.php?gturl=united-states-generic-drugs-market-p.php
Segment: Market breakup from 2 viewpoints
• Generic
• Branded
Therapy Area: Market breakup from 8 viewpoints
1. CNS
2. Cardiovascular
3. Dermatology
4. Genitourinary/Hormonal
5. Respiratory
6. Anti – infective
7. Oncology
8. Others
Pharmaceutical: Market breakup from 2 viewpoints
• Branded Pharmaceutical
• Generics Pharmaceutical
All the Company Analysis have covered 3 Viewpoints
• Overview
• Recent Developments
• Revenue Analysis
Company Analysis
1. Teva Pharmaceutical Industries Ltd
2. Mylan N.V
3. Sandoz Inc.
4. Endo Pharmaceuticals
5. Lupin Limited
6. Dr Reddy’s
7. Sun pharma
Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises of major players in Healthcare, Travel and Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemical, Logistics & Automotive, Consumer Goods & Retail, Building and Construction, & Agriculture. Our clients rely on our market analysis and data to make informed knowledgeable decisions. We are regarded as one of the best providers of knowledge. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.
Our core team is comprised of an experienced people holding graduate, post graduate and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science and many more. Our research helps to make the business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis and forecasting that is essential in today’s ultra-competitive markets.
Renub Research
C-86, C Block, Sector 10
IND201301 Noida
Telefon: +1 (678) 302-0700
Telefax: +91 (120) 421-9822
https://www.renub.com/
E-Mail: rajat.gupta@renub.com
